NASDAQ:PGEN Precigen (PGEN) Stock Price, News & Analysis $0.90 +0.07 (+7.91%) (As of 05:38 PM ET) Add Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Precigen Stock (NASDAQ:PGEN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Precigen alerts:Sign Up Key Stats Today's Range$0.83▼$0.9350-Day Range$0.79▼$1.0752-Week Range$0.77▼$1.93Volume795,755 shsAverage Volume952,104 shsMarket Capitalization$264.43 millionP/E RatioN/ADividend YieldN/APrice Target$7.00Consensus RatingModerate Buy Company OverviewPrecigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.Read More… Urgent: This election is rigged (Ad)If you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Precigen Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks76th Percentile Overall ScorePGEN MarketRank™: Precigen scored higher than 76% of companies evaluated by MarketBeat, and ranked 271st out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingPrecigen has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 4 buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoveragePrecigen has only been the subject of 1 research reports in the past 90 days.Read more about Precigen's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Precigen are expected to grow in the coming year, from ($0.46) to ($0.19) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Precigen is -1.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Precigen is -1.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPrecigen has a P/B Ratio of 4.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.76% of the float of Precigen has been sold short.Short Interest Ratio / Days to CoverPrecigen has a short interest ratio ("days to cover") of 20.1, which indicates bearish sentiment.Change versus previous monthShort interest in Precigen has recently decreased by 0.26%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPrecigen does not currently pay a dividend.Dividend GrowthPrecigen does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.77 Percentage of Shares Shorted10.76% of the float of Precigen has been sold short.Short Interest Ratio / Days to CoverPrecigen has a short interest ratio ("days to cover") of 20.1, which indicates bearish sentiment.Change versus previous monthShort interest in Precigen has recently decreased by 0.26%, indicating that investor sentiment is improving. News and Social Media1.6 / 5News Sentiment-0.10 News SentimentPrecigen has a news sentiment score of -0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Precigen this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for PGEN on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows4 people have added Precigen to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Precigen insiders have not sold or bought any company stock.Percentage Held by Insiders44.90% of the stock of Precigen is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 33.51% of the stock of Precigen is held by institutions.Read more about Precigen's insider trading history. Receive PGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Precigen and its competitors with MarketBeat's FREE daily newsletter. Email Address PGEN Stock News HeadlinesPrecigen (NASDAQ:PGEN shareholders incur further losses as stock declines 13% this week, taking five-year losses to 86%November 20 at 12:49 PM | finance.yahoo.comFY2026 EPS Estimates for Precigen Decreased by HC WainwrightNovember 20 at 4:09 AM | americanbankingnews.com📉 Warning: Market Crash Predicted - Secure Your SavingsThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.November 21, 2024 | Behind the Markets (Ad)Precigen, Inc. (PGEN) Stock Price, News, Quote & History - Yahoo FinanceNovember 17, 2024 | finance.yahoo.comPrecigen’s Promising Developments and Strategic Focus Drive Buy RatingNovember 15, 2024 | markets.businessinsider.comStifel Nicolaus Keeps Their Buy Rating on Precigen (PGEN)November 15, 2024 | markets.businessinsider.comPrecigen, Inc.: Precigen Reports Third Quarter 2024 Financial Results and Business UpdatesNovember 15, 2024 | finanznachrichten.dePrecigen’s Strategic Advancements and FDA Alignment Bolster Buy RatingNovember 15, 2024 | markets.businessinsider.comSee More Headlines PGEN Stock Analysis - Frequently Asked Questions How have PGEN shares performed this year? Precigen's stock was trading at $1.34 at the beginning of 2024. Since then, PGEN stock has decreased by 32.6% and is now trading at $0.9029. View the best growth stocks for 2024 here. How were Precigen's earnings last quarter? Precigen, Inc. (NASDAQ:PGEN) announced its quarterly earnings data on Tuesday, May, 14th. The biotechnology company reported ($0.10) EPS for the quarter, missing analysts' consensus estimates of ($0.09) by $0.01. The biotechnology company earned $1.07 million during the quarter, compared to the consensus estimate of $1.54 million. Precigen had a negative net margin of 3,521.68% and a negative trailing twelve-month return on equity of 123.06%. Who are Precigen's major shareholders? Top institutional investors of Precigen include Iridian Asset Management LLC CT (1.49%), Geode Capital Management LLC (1.28%), State Street Corp (1.14%) and Charles Schwab Investment Management Inc. (0.48%). Insiders that own company stock include Helen Sabzevari, Randal J Kirk, Steven Frank, Jeffrey Thomas Perez, Donald P Lehr, Dean J Mitchell, Jeffrey B Kindler, Harry Jr Thomasian and Rutul R Shah. View institutional ownership trends. How do I buy shares of Precigen? Shares of PGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Precigen own? Based on aggregate information from My MarketBeat watchlists, some other companies that Precigen investors own include Nordic American Tankers (NAT), ZIOPHARM Oncology (ZIOP), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Hess (HES) and Boeing (BA). Company Calendar Last Earnings5/14/2024Today11/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PGEN CUSIPN/A CIK1356090 Webwww.precigen.com Phone(301) 556-9900FaxN/AEmployees202Year FoundedN/APrice Target and Rating Average Stock Price Target$7.00 High Stock Price Target$10.00 Low Stock Price Target$4.00 Potential Upside/Downside+736.6%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-95,900,000.00 Net Margins-3,521.68% Pretax Margin-3,573.10% Return on Equity-123.06% Return on Assets-87.33% Debt Debt-to-Equity RatioN/A Current Ratio1.63 Quick Ratio1.63 Sales & Book Value Annual Sales$6.22 million Price / Sales39.40 Cash FlowN/A Price / Cash FlowN/A Book Value$0.19 per share Price / Book4.40Miscellaneous Outstanding Shares292,870,000Free Float161,371,000Market Cap$245.04 million OptionableOptionable Beta1.68 Social Links 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report This page (NASDAQ:PGEN) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Precigen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Precigen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.